[Palliative treatment of hepatocellular carcinoma].
Doffoël
Michel
M
Hépato-Gastroentérologie, Hôpital Civil, 1 place de l'Hôpital, 67091 Strasbourg Cedex. michel.doffoel@chru-strasbourg.fr
Ananna
Ahmed
A
D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D002945:Cisplatin / Q000008:administration & dosage*; D003627:Data Interpretation, Statistical; D004317:Doxorubicin / Q000008:administration & dosage*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D015201:Meta-Analysis as Topic; D010166:Palliative Care; D011379:Prognosis; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D016898:Interferon-alpha; D004317:Doxorubicin; D002945:Cisplatin